Key Stats for AMGN Stock
- Past-6-Month Performance: 35%
- 52-Week Range: $261 to $390
- Valuation Model Target Price: $350
- Implied Upside: 10%
Value your favorite stocks like Amgen with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Amgen stock is up about 35% over the past six months, recently trading near $388 per share after touching $390, the top of its 52 week range. The rally reflects growing investor confidence in the company’s oncology pipeline expansion, durable profitability profile, and continued institutional participation.
Shares have moved higher as investors reacted to visible commercial traction for IMDELLTRA and expanding late-stage development programs.
This week at Citi’s 2026 Virtual Oncology Leadership Summit, management emphasized that IMDELLTRA is now administered at more than 1,600 U.S. sites following full approval in second-line small cell lung cancer, with three additional Phase III trials underway across first-line and limited-stage settings.
Jean-Charles Soria stated, “We really want to bring the value of this modality to the whole spectrum of the disease,” reinforcing expansion plans that significantly increase the drug’s long-term addressable opportunity.
Pipeline breadth continues to support the move. LUMAKRAS is advancing into earlier-line lung and colorectal cancer Phase III trials, while xaluritamig remains in pivotal development in prostate cancer with overall survival endpoints in both post-taxane and pre-taxane settings.
At the same time, Amgen maintains strong underlying profitability, with gross margins near 71% and EBIT margins above 30%, reinforcing earnings durability into 2026.
Institutional filings show active positioning beneath the surface. Andra AP fonden increased its stake by 306.9% to 47,200 shares worth about $13.32 million, Mitsubishi UFJ Asset Management raised its holdings by 3.7% to 1,237,508 shares valued at roughly $349 million, and Sumitomo Mitsui Financial Group boosted its position by 7.8% to 75,779 shares.
Primecap Management trimmed its stake by 8.7% but still owns 9,707,609 shares worth about $2.74 billion, while Argent Trust reduced its position by 29.4% and Erste Asset Management cut its stake by 21.6%.
The mix of steady accumulation and selective trimming suggests the six-month advance has been driven by structural confidence rather than short-term speculation.
See analysts’ growth forecasts and price targets for Amgen (It’s free) >>>
Is AMGN Overvalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 2.5%
- Operating Margins: 44%
- Exit P/E Multiple: 15x
Revenue is projected to rise from about $36.8 billion in 2025 to roughly $42.5 billion by 2030, reflecting steady contribution from newer oncology assets while mature products moderate.
The most meaningful drivers over the next 12 months include continued uptake of IMDELLTRA as additional Phase III trials progress, earlier-line expansion for LUMAKRAS in KRAS G12C lung and colorectal cancer, and pivotal prostate cancer data for xaluritamig targeting overall survival improvements.
Margin performance remains central. Integration benefits from Horizon assets such as Tepezza and Krystexxa, combined with high-margin oncology growth, support operating leverage even if overall revenue growth remains measured.
Pipeline execution, label expansions, and product mix improvements are likely to matter more in 2026 than headline top-line acceleration.
Based on these inputs, the valuation framework implies downside from current levels if multiples normalize toward historical ranges.
With shares near $388 and trading around 27x trailing earnings versus a modeled 15x exit multiple, Amgen appears overvalued today.
Continued strong execution may support earnings growth, but meaningful upside from multiple expansion looks limited unless growth reaccelerates beyond current expectations.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does AMGN Stock Have From Here?
Investors can estimate Amgen potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See Amgen true value, or any stock’s, in under 60 seconds (Free with TIKR) >>>
